Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Active, not recruiting, industry sponsors, Neurology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed274
11 trials
Showing 1 to 11, recently updated first.
- Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisActive, not recruiting
NCT07246564 · 40 participants · Start Dec 1, 2025 · Primary completion Jun 3, 2027
Drug: Rozanolixizumab · For: Myasthenia Gravis
Sites: Beijing, China; Changchun, China; Changsha, China · 12 sites in all
- Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple SclerosisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04480853 · 14 participants · Start Oct 12, 2020 · Primary completion Oct 15, 2026
Drug: Fingolimod · For: Multiple Sclerosis
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Taipei, Taiwan
- Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyActive, not recruiting
SK Life Science, Inc.Industry
NCT06453213 · 49 participants · Start Oct 14, 2024 · Primary completion May 26, 2027
Drug: Cenobamate · For: Focal Onset Seizure
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 19 sites in all
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07483450 · 60 participants (planned) · Start Jul 4, 2025 · Primary completion Dec 31, 2027
Drug: Ocrelizumab · For: Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis
Sites: Nanchang, China; Beijing, China; Changsha, China · 17 sites in all
- Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05044819 · 154 participants · Start Jul 7, 2021 · Primary completion Aug 1, 2027
Drug: Cannabidiol · For: Lennox Gastaut Syndrome; Dravet Syndrome; Tuberous Sclerosis Complex
Sites: Little Rock, Arkansas; Downey, California; Long Beach, California · 26 sites in all
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruiting
BiogenBiogen (BIIB)
NCT07223723 · 12 participants (planned) · Start Dec 11, 2025 · Primary completion May 26, 2027
Drug: Tofersen · For: Amyotrophic Lateral Sclerosis
Sites: Beijing, China
- Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple SclerosisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06444113 · 24 participants · Start Nov 25, 2024 · Primary completion Feb 20, 2026
Drug: Ofatunumab · For: Multiple Sclerosis
Sites: San Francisco, California; Aurora, Colorado; Winfield, Illinois · 15 sites in all
- A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05090371 · 136 participants · Start Mar 2, 2022 · Primary completion Apr 13, 2027
Drug: Ofatumumab; Disease modifying treatment (DMT) · For: Relapsing-Remitting Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Chandler, Arizona · 43 sites in all
- A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06396039 · 84 participants (planned) · Start May 15, 2024 · Primary completion Dec 29, 2028
Drug: BMS-986374 · For: Relapsing Multiple Sclerosis
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 25 sites in all
- A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)Active, not recruiting
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.Industry
NCT05058040 · 2,500 participants · Start Jun 2, 2021 · Primary completion Jan 2025
Drug: Sodium Oligomannate Capsules · For: Alzheimer Disease
Sites: Hefei, China; Beijing, China; Chongqing, China · 63 sites in all
- Long-term Efficacy and Safety Study of GV-971Active, not recruiting
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.Industry
NCT05181475 · 800 participants · Start Dec 7, 2021 · Primary completion Jan 2025
Drug: Sodium Oligomannate Capsules (GV-971) · For: Alzheimer Disease
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 40 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.